Literature DB >> 15728186

Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry.

Matthew B Renfrow1, Helen J Cooper, Milan Tomana, Rose Kulhavy, Yoshiyuki Hiki, Kazunori Toma, Mark R Emmett, Jiri Mestecky, Alan G Marshall, Jan Novak.   

Abstract

In a number of human diseases of chronic inflammatory or autoimmune character, immunoglobulin molecules display aberrant glycosylation patterns of N- or O-linked glycans. In IgA nephropathy, IgA1 molecules with incompletely galactosylated O-linked glycans in the hinge region (HR) are present in mesangial immunodeposits and in circulating immune complexes. It is not known whether the Gal deficiency in IgA1 proteins occurs randomly or preferentially at specific sites. To develop experimental approaches to address this question, the synthetic IgA1 hinge region and hinge region from a naturally Gal-deficient IgA1 myeloma protein have been analyzed by 9.4 tesla Fourier transform-ion cyclotron resonance mass spectrometry. Fourier transform-ion cyclotron resonance mass spectrometry offers two complementary fragmentation techniques for analysis of protein glycosylation by tandem mass spectrometry. Infrared multiphoton dissociation of isolated myeloma IgA1 hinge region peptides confirms the amino acid sequence of the de-glycosylated peptide and positively identifies a series of fragments differing in O-glycosylation. To localize sites of O-glycan attachment, synthetic IgA1 HR glycopeptides and HR from a naturally Gal-deficient polymeric IgA1 myeloma protein were analyzed by electron capture dissociation and activated ion-electron capture dissociation. Multiple sites of O-glycan attachment (including sites of Gal deficiency) in myeloma IgA1 HR glycoforms were identified (in all but one case uniquely). These results represent the first direct identification of multiple sites of O-glycan attachment in IgA1 hinge region by mass spectrometry, thereby enabling future characterization at the molecular level of aberrant glycosylation of IgA1 in diseases such as IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728186     DOI: 10.1074/jbc.M411368200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

Review 1.  Mass spectrometry based glycoproteomics--from a proteomics perspective.

Authors:  Sheng Pan; Ru Chen; Ruedi Aebersold; Teresa A Brentnall
Journal:  Mol Cell Proteomics       Date:  2010-08-24       Impact factor: 5.911

2.  Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.

Authors:  Michelle M Gomes; Hitoshi Suzuki; Monica T Brooks; Milan Tomana; Zina Moldoveanu; Jiri Mestecky; Bruce A Julian; Jan Novak; Andrew B Herr
Journal:  Biochemistry       Date:  2010-07-13       Impact factor: 3.162

3.  Naturally occurring structural isomers in serum IgA1 o-glycosylation.

Authors:  Kazuo Takahashi; Archer D Smith; Knud Poulsen; Mogens Kilian; Bruce A Julian; Jiri Mestecky; Jan Novak; Matthew B Renfrow
Journal:  J Proteome Res       Date:  2011-12-29       Impact factor: 4.466

Review 4.  Mass spectrometry based proteomics in urine biomarker discovery.

Authors:  Dan Theodorescu; Harald Mischak
Journal:  World J Urol       Date:  2007-08-17       Impact factor: 4.226

Review 5.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

6.  High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine.

Authors:  Harald Mischak; Bruce A Julian; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2007-07-10       Impact factor: 3.494

7.  Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes.

Authors:  Azusa Hashimoto; Yusuke Suzuki; Hitoshi Suzuki; Isao Ohsawa; Rhubell Brown; Stacy Hall; Yuichi Tanaka; Jan Novak; Hiroyuki Ohi; Yasuhiko Tomino
Journal:  Am J Pathol       Date:  2012-08-05       Impact factor: 4.307

8.  Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.

Authors:  Francois Berthoux; Hitoshi Suzuki; Lise Thibaudin; Hiroyuki Yanagawa; Nicolas Maillard; Christophe Mariat; Yasuhiko Tomino; Bruce A Julian; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

9.  Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding.

Authors:  Michelle M Gomes; Stephanie B Wall; Kazuo Takahashi; Jan Novak; Matthew B Renfrow; Andrew B Herr
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

Review 10.  Pathogenesis of Henoch-Schönlein purpura nephritis.

Authors:  Keith K Lau; Hitoshi Suzuki; Jan Novak; Robert J Wyatt
Journal:  Pediatr Nephrol       Date:  2009-06-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.